The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical Roundup

Phase III KEYNOTE-522 trial meets dual primary endpoint of event-free survival in high-risk early-stage TNBC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The phase III KEYNOTE-522 trial investigating Keytruda in combination with chemotherapy as neoadjuvant treatment and then continuing as an adjuvant treatment after surgery met its dual primary endpoint of event-free survival for the treatment of patients with high-risk early-stage triple-negative breast cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Lou Weiner: Poetry and art help us imagine my mother’s world as a hidden child of the Holocaust

I write a weekly blog for Georgetown University’s Lombardi Comprehensive Cancer Center community. Here I share an updated version of a blog post I wrote in September 2024, now supplemented by some poems I have written over the years that inspired paintings by my wife Harriet Weiner, who is a much better artist than I am a poet or writer. 
By Louis M. Weiner
Cancer Policy

Trump administration broke law by canceling DEI research grants, GAO finds

The Government Accountability Office, an independent, non-partisan congressional watchdog agency, found that NIH violated the Impoundment Control Act of 1974 when it cancelled nearly 2,000 research grants in an effort to comply with several of President Donald Trump’s executive orders, including “Ending Radical And Wasteful Government DEI Programs And Preferencing” (The Cancer Letter, Jan 24, 2025).
By Jacquelyn Cobb
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account